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Signal transduction pathways convey signals generated at the cell surface into the cell nucleus in order to
initiate a program of gene expression that is characteristic for particular stimuli. Here we present evidence that
infection by herpes simplex virus type 1 activated the two terminal kinases, cJUN N-terminal kinase (JNK) and
p38, of stress-activated signal transduction kinase cascades. By using a solid-phase kinase assay, a phospho-
specific antibody, and extracts prepared from a variety of infected cell types, we determined that activation of
both kinases began 3 to 4 h postinfection (p.i.) and remained elevated out to 14 h p.i. Through the use of
UV-irradiated or antibody-neutralized wild-type virus and the temperature-sensitive mutant tsB7, the high
level of JNK activation was shown to be dependent on viral gene expression. Activation of JNK following
infection by vi13, an ICP4 mutant virus that does not express early or late genes, suggested that only virus entry
and immediate-early gene expression were necessary for JNK activation. The activation of JNK and p38
correlated with increased chloramphenicol acetyltransferase (CAT) activity in reporter assays dependent upon
the activity of cJUN and ATF2 trans-activation domains. Increased CAT activity dependent on TRE and CRE
promoter sites was also observed in response to herpes simplex virus infection. The activities of ERK and
ERK-dependent transcription factors were unchanged or depressed following infection, showing that activation
of JNK and p38 was a specific event. Finally, the activation of JNK was important for the efficiency of viral
replication. The yield of virus in NIH 3T3 cells stably expressing JIP-1, an inhibitor of JNK translocation to
the nucleus, was reduced 70% compared to that of control cells, in single-step growth experiments.
The cell’s ability to sense external stimuli and to react by
initiating a program of gene expression often involves propa-
gation of a cell surface-initiated signal along a specific path-
way(s) of protein kinases whose ultimate targets are nuclear-
acting transcription factors. Conditions such as the type of
stimulus, duration of stimulation, and cell type can all play
roles in whether the transduced signals are interpreted as
growth stimulatory (proliferative), growth inhibitory (differen-
tiating), or apoptotic (death inducing) (40, 52, 75, 92). The
prototypical signal transduction pathway is the mitogenic path-
way. This pathway is initiated when growth factors bind to and
activate their cognate growth factor receptors on the surface of
the cell. Activation of the receptor leads to the membrane-
bound G-protein, RAS, adopting an active GTP-bound state
(18, 48, 75). RAS is critical for coordinating the activation of a
serine/threonine kinase called RAF (5, 18). RAF then initiates
a kinase cascade by phosphorylating and activating two highly
related dual-specific kinases, MEK1 and MEK2, which in turn
phosphorylate two highly related serine/threonine kinases,
ERK1 and ERK2 (11, 12, 15, 75). Upon activation, ERKs can
migrate into the nucleus and activate transcription factors such
as cMYC and ELK1 by phosphorylating their trans-activation
domains (TADs) (2, 7, 9, 28, 29, 32). These transcription fac-
tors can induce the expression of cdc25 and c-fos, respectively,
for example, which are important for promoting cell cycle
progression into S phase (3, 7, 25, 28, 47).
Kinases analogous to the ERKs and pathways parallel to the
RAF-MEK-ERK pathway have been described. The related
terminal serine/threonine kinases, which include the ERKs,
are collectively referred to as mitogen-activated protein ki-
nases (MAPKs). MEK1/2 now belongs to a class of proteins
known as MAPK kinases (MAPKKs), and RAF and related
kinases are called MAPKK kinases (MAPKKKs). The most
well characterized of these analogous pathways are called the
stress-activated protein kinase (SAPK) pathways, because
stresses such as UV exposure and high osmolarity lead to their
activation (40, 52, 92). JNK1-3 (cJUN N-terminal kinase) and
p38, sometimes collectively referred to as SAPKs, are the
MAPKs for these pathways, and corresponding MAPKKs and
MAPKKKs have been characterized that specifically activate
JNKs and/or p38 (40, 52, 92). The transcription factor ATF2 is
a target for both p38 and JNKs, while the JNKs can also
phosphorylate cJUN (33, 55, 86).
Viruses are ultimately dependent upon the host cell for their
replication. Because they reorganize or utilize various cellular
functions, it seems likely that viruses would take advantage of
the preexisting signaling pathways to induce cellular and/or
viral gene expression to promote viral replication. Indeed,
studies characterizing the effects of infection by other viruses,
such as bovine papillomavirus (60), vaccinia virus (50), simian
virus 40 (83), human immunodeficiency virus type 1 (41), and
herpesvirus saimiri (44), have shown a dependence upon ERK
cascade signaling for replication, and in some cases, viral pro-
teins have been identified that induce activation of ERKs.
Additionally, other studies have described activation of differ-
ent MAPKs, but the purposes for their activation following
infection remain unclear (20, 71, 81, 100).
During lytic infection by herpes simplex virus (HSV) in per-
missive cells, there are increases in activities of AP-1 (42) and
NF-kB (30, 68, 77), both of which are downstream targets of
SAPK pathways (53, 57, 92), suggesting that these pathways
may be activated. Additionally, there is evidence that infection
by HSV inhibits cell cycle progression, raising the possibility
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that ERK activity, which promotes progression, is inhibited
(14, 19). We present data here to support these predictions.
We show that not only are SAPK pathways activated following
infection, but activation of one SAPK, JNK, promotes efficient
viral replication. ERK and ERK-dependent activities are not
activated following infection. In agreement with our data is a
recent report which also showed the activation of JNK and p38
following HSV infection (100).
MATERIALS AND METHODS
Cells and virus. NIH 3T3, U2OS, C33, and Vero cells were grown and main-
tained in Dulbecco’s modified Eagle’s media (DMEM) supplemented with 2 mM
L-glutamine. For growth of NIH 3T3 cells (originally obtained from Channing
Der, UNC—Chapel Hill), the medium was supplemented with 10% bovine calf
serum, while that for the Vero cells contained 5% bovine calf serum. DMEM for
U2OS and C33 cells was supplemented with the addition of 10% fetal calf serum.
BHK-21 cells were grown and maintained in alpha minimum essential media
supplemented with L-glutamine as described above and 10% fetal calf serum.
The G13.5 and G14.1 cell lines were established via stable transfection of NIH
3T3 cells with either a pcDNA3 empty vector or a pcDNA3 JIP-1-expressing
vector, respectively. The JIP-1 vector (17) was provided by Roger Davis (Uni-
versity of Massachusetts Medical Center). These cells were selected and main-
tained in media supplemented with 600 mg of G418 (Geneticin; Gibco BRL) per
ml. All experiments were performed with the KOS strain of HSV-1, unless
otherwise noted. tsB7, provided by David Knipe (Harvard University), is a
temperature-sensitive mutant derived from the HFEM strain of HSV-1 (4, 51).
The virus mutant vi13, provided by Neal DeLuca (University of Pittsburgh),
encodes an ICP4 containing a small insertion at amino acid (aa) 338, which
reduces ICP4’s affinity for DNA, prevents early and late gene expression, and
results in overexpression of immediate-early (IE) proteins (reference 82 and this
report).
Antibodies. ERK1 (C-16) and JNK1 (FL) antibodies were purchased from
Santa Cruz Biotechnology, Inc. p38 (no. 9212) and phospho-p38 (no. 9211)
antibodies (New England Biolabs) were a gift from Eng-Shang Huang. Mouse
monoclonal antibodies to viral IE proteins ICP0 (1083) and ICP4 (H943) were
obtained from Lenore Pereira (University of California at San Francisco). Rab-
bit polyclonal antibody to viral replication protein ICP8 was originally obtained
from Ken Powell (Burroughs Wellcome). Rabbit polyclonal antibody against
viral glycoprotein gC (Ab47) and monoclonal antibody against viral glycoprotein
gB (SS10) were obtained from Roselyn Eisenberg and Gary Cohen (University
of Pennsylvania). Monoclonal antibodies against viral glycoproteins gD (III 174-
1.2), gH (52S), and gC (VII 13-7) were provided by Patricia Spear (Northwestern
University). To neutralize HSV, the amount of gB, gD, and gH antibody added
was enough to reduce virus titer by at least 2 orders of magnitude. Based on the
relative quantity of antibody used for each of the neutralization experiments, an
equal amount of antibody protein to gC was used in control experiments. Anti-
mouse and antirabbit secondary antibodies were obtained from Santa Cruz
Biotechnology, Inc.
CAT Assays. Each effector plasmid used encodes a fusion protein containing
the yeast GAL4 DNA-binding domain and the TAD of the respective transcrip-
tion factor. The 53GAL-CAT reporter plasmid (54) encodes the bacterial chlor-
amphenicol acetyltransferase (CAT) protein and contains GAL4 DNA-binding
sites in the promoter. The 2AP1CAT reporter plasmid (90) contains two con-
sensus AP-1 sites upstream of the CAT gene. The 33CRECAT reporter plasmid
contains three copies of the CRE consensus sequence upstream of the adeno-
virus E1b promoter and the CAT gene.
For each assay, 5 3 105 NIH 3T3 or BHK-21 cells in 60-mm-diameter dishes
were transfected by the calcium phosphate precipitation procedure (31) with 2.5
mg of a 53GAL-CAT reporter and the indicated amount of one of the following
effectors: 150 ng of GAL-ELK1 (58), 500 ng of GAL-cFOS, 500 ng of GAL-
cMYC (2), 500 ng of GAL-cJUN (37), 500 ng of GAL-ATF2, or 250 ng of
GAL-RELA (80). In experiments using the pZIP vectors, 250 ng of pZIP-
RAS15A (8), 200 ng (unless stated otherwise) of CDC25X (72), or equivalent
amounts of the empty pZIP vector were cotransfected with 53GAL-CAT and
either GAL-cJUN or GAL-ATF2. Other dishes were transfected with 2.5 mg of
2AP1CAT or 33CRECAT reporter. Eighteen hours after transfection, the cells
were refed, and 12 h later, the cells were either mock infected or infected with
HSV KOS (multiplicity of infection [MOI] 5 5). Eighteen hours postinfection
(p.i.) the cells were harvested. CAT assays were performed (31) with equivalent
amounts of protein from each sample. Results were quantitated on an AMBIS
scanner and were the average of at least three separate experiments, except in
Fig. 2A, which was performed only once.
Lipofectamine reagent (GIBCO BRL) was also used to transfect cells in some
experiments as indicated. Opti-Mem (GIBCO BRL) (400 ml) was mixed with the
previously described amount of DNA, and another 400 ml of Opti-Mem was
mixed with 8 ml of Lipofectamine. The two solutions were mixed and allowed to
sit at room temperature for 30 min. An additional 2.2 ml of Opti-Mem was added
to each solution prior to overlaying the cells that had been rinsed with Opti-
Mem. Cells were refed with fresh medium at 5 and 18 h posttransfection and
were then infected and harvested as described above.
Kinase assays. Cells were mock infected or infected with KOS (MOI 5 5) and
harvested at the indicated times p.i. to produce whole-cell lysates. Kinase assays
were performed as described in reference 37. Cells were washed in phosphate-
buffered saline and frozen in lysis buffer (25 mM HEPES [pH 7.7], 300 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100 plus inhibitors: 0.5 mM
dithiothreitol, 20 mM b-glycerophosphate, 0.1 mM Na3VO4, 2 mg of leupeptin/
ml, 100 g of phenylmethylsulfonyl fluoride/ml, 1 mM NaF, and 1 mg of aprotinin/
ml). Cells were allowed to thaw and lyse at 4°C for 4 to 5 h. Samples were then
clarified by spinning at 13,000 3 g for 10 min at 4°C. For each sample, a volume
of the resulting supernatant, representing an equivalent number of cells, was
diluted (final concentrations: 20 mM HEPES, 75 mM NaCl, 2.5 mM MgCl2, 0.01
mM EDTA, 0.05% Triton X-100 plus inhibitors). To precipitate JNK, 10 mg of
glutathione S-transferase (GST)-cJUN (for JNK assays) was conjugated to GST-
Sepharose beads and incubated overnight with lysates. In the assays utilizing
GST-ATF2, 6 mg of that substrate was added to each sample. After extensive
washing (wash buffer: 20 mM HEPES (pH 7.7), 50 mM NaCl, 2.5 mM MgCl2, 0.1
mM EDTA, 0.05% Triton X-100), the beads were incubated in kinase buffer (20
mM HEPES [pH 7.6] and 20 mM MgCl2 plus 20 mM b-glycerophosphate, 20
mM p-nitrophenyl phosphate, 0.1 mM Na3VO4, 2 mM dithiothreitol, 1 mM NaF,
20 M ATP) with 5 mCi of [g-32P]ATP per reaction for 30 min at 30°C. Samples
were diluted 1:2 in 23 sample buffer, boiled, and fractionated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 12% polyacrylamide
gels. Experiments using the viral glycoprotein antibodies were performed after
the virus had been incubated with the antibodies for 1 h at 37°C prior to infecting
the cells. For the ERK assays, cells were placed in 0.5% serum for 24 h prior to
infection. The diluted extracts were first precleared with normal rabbit serum
and protein A beads. ERK1 antibody was added and allowed to incubate for at
least 5 h, and then protein A beads were added for an overnight incubation. After
washing, the beads were resuspended in kinase buffer with [g-32P]ATP and 10 mg
of myelin basic protein as a substrate and incubated for 30 min at 30°C. Samples
were diluted 1:2 in 23 sample buffer, boiled, and fractionated by SDS-PAGE on
15% polyacrylamide gels.
Immunoblotting. Fractionated extracts were prepared as described by Hilton
et al. (39). Cell equivalent amounts of cellular lysates prepared for JNK kinase
assays were run on 10 or 12% polyacrylamide-SDS gels. Proteins were trans-
ferred to a polyvinylidene difluoride (PVDF) membrane and probed for JNK,
ERK, p38, or activated p38 or the indicated viral proteins. Membranes were
blocked in TBST (150 mM NaCl, 20 mM Tris [pH 7.5], 0.05% Tween 20) with
3% milk, and all probing and washing was done in TBST with 0.5% milk. The
secondary antibody was detected with the Renaissance chemiluminescence re-
agent (DuPont NEN).
Single-step growth assays. NIH 3T3 cells (G13.5 and G14.1) were seeded
(2.5 3 105) into 60-mm-diameter dishes and infected the next day with HSV-1
KOS (MOI 5 5). Cells and supernatant were harvested at the indicated times p.i.
and frozen and thawed four times. Virus titers were determined by plaque assays
on Vero cells. Each titration was done in triplicate, and each point represents
three independent experiments.
RESULTS
HSV induces the trans-activation function of cJUN and
ATF2 via a RAS-independent mechanism. As a first means of
investigating how HSV may be affecting cellular signal trans-
duction pathways, we assessed the activities of the endpoints of
several of these pathways by determining the activity of various
transcription factors known to be phosphorylated and acti-
vated by different MAPKs. In these experiments, NIH 3T3
cells were cotransfected with a CAT reporter plasmid contain-
ing five GAL4 DNA-binding sites upstream of the CAT coding
sequence and one of a set of plasmids that encodes a fusion
protein containing the GAL4 DNA-binding domain and the
TAD of a transcription factor. This experimental design ne-
gates any differences in DNA binding and focuses solely on the
trans-activation ability of the various recombinant transcription
factors. We utilized NIH 3T3 cells because the response of
transcription factors to signals mediated by MAPK pathways
and the methodology using these constructs in similar experi-
ments to study these responses have been well characterized in
this cell line (10, 35, 49, 70, 90, 94). Figure 1A shows the results
of the CAT assays. Infection of transfected cells by HSV re-
pressed the level of CAT activity when the effector was GAL-
cMYC, GAL-ELK1, or GAL-RELA. GAL-cFOS-dependent
CAT activity was relatively unaffected by infection. In contrast,
CAT activity in extracts from HSV-infected cells transfected
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with GAL-cJUN or GAL-ATF2 was increased 20-fold over
that detected in mock-infected extracts. (Note differences in
scale among the assays for different effectors.) No CAT activity
was detected in any extracts, mock or infected, in the absence
of a transfected effector construct (negative data not shown).
It has been reported that HSV infection causes an increase
in AP-1 activity (42). AP-1 is a dimeric transcription factor
composed either of one JUN family member and one FOS
family member or of two JUN family members (3, 46). The
cognate binding site for AP-1, the tetradecanoyl phorbol ace-
tate (TPA)-responsive element (TRE), is TGACTCA. JUN
can also heterodimerize with CREB family members such as
ATF2, and these complexes bind to a related sequence called
the cyclic AMP-responsive element (CRE), TGACGTCA (3,
46). We confirmed that HSV infection increased AP-1 activity
in both NIH 3T3 and BHK-21 cells by using a CAT reporter,
2AP1CAT, containing two consensus AP-1 binding sites (TRE
sequences) in the upstream region (Fig. 1B). Since we ob-
served increased GAL-ATF2-dependent CAT activity, CRE-
dependent promoter activity was also measured with 33CRE-
CAT. In this case, we observed no change in CRE-dependent
activity in NIH 3T3, where the constitutive level was high. In
BHK-21 cells, however, where constitutive activity was low, we
observed a two-and-a-half-fold increase in CRE-dependent
CAT activity after infection (Fig. 1B).
The presence of growth factors and mitogens upregulates
RAS activity. Activated RAS in turn coordinates the induction
of the RAF-MEK-ERK pathway, which upregulates the activ-
ity of some transcription factors, such as cMYC and Ets (6, 87).
Growth factors only weakly activate JNK, and hence cJUN, in
a RAS-dependent manner (46, 95). cJUN can also be activated
by pathways that are not RAS dependent (5, 6, 61, 62, 87).
These pathways, however, are inhibited by activated RAS,
since the absence of activated RAS results in modest increases
in cJUN activity (5, 6, 61, 62, 87). To ascertain whether the
activation of cJUN and ATF2 detected after infection was
dependent upon RAS, we repeated the CAT assays and in-
cluded an expression vector that encoded a dominant-negative
version of RAS, RAS15A, or a constitutively active version of
CDC25, CDC25X. RAS15A can still bind to guanine exchange
factors (GEFs), but it is unable to release GDP in exchange for
GTP (8). RAS15A, therefore, sequesters GEFs into nonpro-
ductive complexes and inhibits the activation of wild-type
RAS. CDC25X is a truncated, membrane-localized form of
CDC25, a RAS GEF. Due to its membrane localization, it can
constitutively interact with and activate RAS (72).
In NIH 3T3 cells, cJUN can be regulated by a RAS-depen-
dent pathway, since constitutively activated CDC25 increased
GAL-cJUN-dependent CAT activity (Fig. 2A, lanes 1 to 4),
while dominant-negative RAS (acting downstream of CDC25)
reversed this increase (Fig. 2A, lanes 5 to 7). In HSV-infected
cells, however, neither a dominant-negative RAS nor a consti-
tutively active CDC25 had any effect on the observed increase
in GAL-cJUN-dependent activity (Fig. 2B, lanes 2, 4, and 6),
while both these effectors caused an increase in GAL-cJUN
activity in mock-infected cells (Fig. 2B, lanes 1, 3, and 5). Thus
while cJUN can be weakly activated by a RAS-dependent
mechanism in uninfected NIH 3T3 cells, this pathway does not
significantly contribute to GAL-cJUN activation in HSV-in-
fected cells. Inhibition of RAS activity (e.g., expression of
RAS15A) can derepress pathways that also modestly activate
cJUN as seen when comparing mock-infected pZIP- and pZIP-
RAS15A-transfected cells (Fig. 2B, lanes 1 and 3). In contrast,
there is no difference between HSV-infected pZIP- and
pZIPRAS15A-transfected cells (Fig. 2B, lanes 2 and 4). When
RAS15A was cotransfected with CDC25X, the level of CAT
activity was restored to that seen in cells transfected with the
reporter and GAL-cJUN alone (Fig. 2B, compare lanes 1 and
2 to lanes 7 and 8). Expression of the dominant-negative RAS
had no effect on GAL-ATF2-dependent CAT activity in mock-
or virus-infected cells (Fig. 2B, lanes 9 to 12). Furthermore,
none of the pZIP vectors had any effect on the level of activity
expressed from 53GAL-CAT in the absence of GAL-cJUN or
GAL-ATF2, because these samples had no detectable CAT
activity (negative data not shown). Thus, even RAS-indepen-
dent cellular pathways are not contributing to virus-induced
cJUN activity.
HSV activates SAPKs but not ERK. We next focused our
study on the possible activation of JNK and p38 as suggested
by increased GAL-cJUN and GAL-ATF2 activity in the CAT
assays. We also assayed the activity of another MAPK, ERK,
that the CAT data suggested either decreased or remained
unchanged following infection. We first performed in vitro
solid substrate and immune complex kinase assays for JNK and
FIG. 1. HSV activates the TAD of cJUN and ATF2 and stimulates AP-1
activity. (A) NIH 3T3 cells (5 3 105) were transfected with 2.5 mg of a 53GAL-
CAT reporter and 150 to 500 ng of the various effectors, each of which encodes
a fusion protein containing the GAL4 DNA-binding domain and the TAD of the
respective transcription factors. Under each effector heading is the reported
MAPK, if known, that activates the TAD of that transcription factor. (B) NIH
3T3 or BHK-21 cells (5 3 105) were transfected with 2.5 mg of 2AP1CAT or
33CRECAT reporter. 2AP1CAT contains two consensus AP-1 sites upstream of
the CAT gene. 33CRECAT contains three copies of the CRE in front of the
adenovirus E1b promoter upstream of the CAT gene. For all CAT experiments,
cells were refed 18 h after transfection, and 12 h later, the cells were either mock
infected or infected with KOS (MOI 5 5). Eighteen hours p.i., the cells were
harvested. CAT assays were performed with equivalent amounts of protein from
each sample. Results were quantitated on an AMBIS scanner and are the
average of at least three separate experiments.
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ERK, respectively. The results from five different cell types are
shown in Fig. 3. We used NIH 3T3 cells to directly correlate
any differences we saw in kinase activation with the CAT data
(Fig. 1). We also chose to study Vero and BHK-21 cells be-
cause they are commonly used for studies of HSV replication,
and C33-A and U2OS cells to show that the effects also oc-
curred in human cells. Although there was some variability in
the degree to which JNK was activated, all cell types tested
demonstrated upregulation of JNK following infection with
HSV, as indicated by phosphorylation of a wild-type GST-
cJUN substrate (Fig. 3A, upper panel of each cell type set).
The induction was greater than 20-fold in all but NIH 3T3 cells
(6-fold), comparable to the level seen when the cells were
treated with the protein synthesis inhibitor, anisomycin, a po-
tent inducer of JNK activity (22, 36, 96). JNK phosphorylates
serines 63 and 73 in the amino terminus of cJUN (16, 37).
When a GST-cJUN substrate was used in which Ser63 and
Ser73 were mutated to alanines (AA), phosphorylation of
GST-cJUN was abolished. Coomassie blue staining of the gels
prior to autoradiography showed that all lanes contained equal
amounts of substrate (data not shown).
The lower panel for each cell type set is an immunoblot for
JNK demonstrating the amount of JNK which was precipitated
in each experiment was constant. These results provide evi-
dence that infection was activating preexisting JNK rather than
inducing JNK expression. Because the kinase whose activity we
detected must be precipitable by binding to the amino termi-
nus of cJUN, and because the specificity of the phosphoryla-
tion of GST-cJUN in infected cells was identical to that seen in
anisomycin-induced control cells, we conclude that we are de-
tecting bona fide JNK activity. In support of this conclusion, we
have obtained identical results when using an antibody against
JNK to immunoprecipitate the kinase for use in immune com-
plex kinase assays with GST-cJUN as the substrate (data not
shown). Thus, activation of JNK upon HSV infection is a
FIG. 2. Activation of cJUN and ATF2 TADs is RAS independent. (A) NIH
3T3 cells (5 3 105) were transfected with 2.5 mg of a 53GAL-CAT reporter, 500
ng of GAL-c-JUN, and various amounts of pZIP-CDC25X, with or without 250
ng of pZIP-RAS15A. An adjusted amount of pZIP vector was added accordingly
to equalize the amount of transfected DNA between the samples. (B) NIH 3T3
cells (5 3 105) were transfected with 2.5 mg of a 53GAL-CAT reporter and 500
ng of either GAL-c-JUN or GAL-ATF-2 and either 250 ng of pZIP-RAS15A,
200 ng of pZIP-CDC25X, or equivalent amounts of empty pZIP vector. For all
CAT experiments, cells were refed 18 h after transfection, and 12 h later, the
cells were either mock infected or infected with KOS (MOI 5 5). Eighteen hours
p.i., the cells were harvested. CAT assays were performed with equivalent
amounts of protein from each sample. Results were quantitated on an AMBIS
scanner and are the average of at least three separate experiments, except in
panel A, which was performed only once.
FIG. 3. HSV activates JNK but not ERK. (A) BHK-21, U2OS, NIH 3T3,
Vero, and C33-A cells were mock infected, infected with KOS (MOI 5 5) for
10 h, or treated with anisomycin (20 mg/ml) for 20 min. Cells were then harvested
to produce lysates. Equivalent numbers of cells were assayed in each sample. The
top panel for each cell type is the result of an in vitro solid substrate kinase assay
using 10 mg of GST-cJUN (aa 1 to 79) conjugated to GST-Sepharose beads, as
described in Materials and Methods. Two different GST-cJUN substrates were
used: a wild-type (WT) GST-cJUN and a mutant (AA) GST-cJUN. In the
mutant construct, the serines that are phosphorylated to cause cJUN trans-
activation (serines 63 and 73) have been mutated to alanines. The bottom panel
for each cell type is an immunoblot, probed with an antibody to JNK, performed
on a fraction of the pull down. (B) The same cell types used in panel A were used
to compare the level of ERK activity in mock-infected cells (M) versus infected
cells at 10 h p.i. (I). The top panel shows results from an in vitro immune complex
kinase assay for ERK on extracts from serum-starved cells, as described in
Materials and Methods. The bottom panel is an immunoblot from a fraction of
the immunoprecipitation probed with an antibody against ERK.
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universal response, regardless of the species origin or cell type
assayed.
Similar assays to detect ERK activity indicated no change in
the level of ERK activity as a result of infection (Fig. 3B). The
experiment in Fig. 3B was performed on serum-starved cells to
reduce the ERK kinase activity background so as to more
easily detect any increases in activity that may have been in-
duced by infection. In all cell types tested, no change in ERK
activity (Fig. 3B, upper panel) was detected in comparing
mock-infected cells (M) to cells infected with KOS for 10 h (I).
In the few cases in which differences were detected, the change
could be accounted for by variability in the amount of ERK
protein that was brought down in individual immunoprecipi-
tations (Fig. 3B, lower panel). Kinase assays detecting ERK
activity were also performed with cells grown under normal
culture conditions. In these experiments, the background ERK
activity was high, and no increases in activity could be detected.
In fact, slight decreases were often detected (data not shown).
Thus, the CAT assay results were predictive of how HSV
affected the activity of various MAPKs responsible for phos-
phorylating and activating the TADs of the assayed transcrip-
tion factors. Upregulation of JNK correlated well with in-
creased GAL-cJUN-dependent CAT activity, while ERK was
unaffected or slightly downregulated, as mirrored by the down-
regulation, for example, of GAL-cMYC-dependent CAT ac-
tivity.
The data in Fig. 3 were from cells that had been infected for
10 h. To determine the kinetics and magnitude of JNK activa-
tion as well as to detect any transient activation of the MAPKs,
we repeated the kinase assays over a time course of infection in
U2OS cells (Fig. 4). Using GST-cJUN in solid substrate kinase
assays (top two panels of Fig. 4A), we detected little or no JNK
activity in mock-infected cells, but increased JNK activity was
detected between 3 and 5 h p.i. in virus-infected cells. The
activity increased 20-fold by 9 h p.i. when it appeared to pla-
teau. It should be noted that great care had to be taken during
infection to minimize cell exposure to air, because this situa-
tion could induce a transient JNK activation (data not shown).
Repeating the assay with GST-ATF2 as the substrate, we
saw similar kinetics for kinase activation, but the activation was
much reduced in magnitude (lower two panels of Fig. 4A).
Both JNK and p38 are capable of binding to and phosphory-
lating ATF2, although ATF2 is a better substrate for p38 than
it is for JNK (33, 73). To determine if p38 was playing a role in
the phosphorylation of GST-ATF2 or whether JNK is solely
activated, we decided to investigate p38’s activation state as a
result of infection. We infected U2OS cells over a similar time
course and harvested samples to use for immunoblotting. We
probed the immunoblots with a phospho-specific antibody that
recognizes p38 phosphorylated on threonine 180 and tyrosine
182. Phosphorylation of these two residues correlates with
activation of p38 (73). The use of an antibody that recognizes
these two residues when dually phosphorylated, therefore,
should be equivalent to doing direct kinase assays for deter-
mining p38 activation, as has been determined by other labo-
ratories (64, 71). Figure 4B shows that over a time course, an
activated form of p38 was detected in the infected samples
(HSV p-p38 panel) with similar kinetics as was seen for the rise
in JNK activation (Fig. 4A, top HSV panel). No activation of
p38 was seen in the mock samples (Mock p-p38 panel). De-
spite some fluctuations in total p38 in the mock samples of this
representative experiment (Mock p38 panels), infection by
HSV induced activation of p38 without affecting the level of
total p38 (HSV p-p38 and p38 panels). This result confirmed
that both JNK and p38 are activated at relatively the same time
p.i., and their activities remain high out to 11 h p.i.
Immune complex kinase assays for ERK showed no change
in activity over the time course of infection (Fig. 4C). The
failure to detect an induction in ERK was not due to limiting
substrate or antibody in immunoprecipitation or kinase reac-
tions, because increases in both did not result in any higher
ERK activity (data not shown). Identical results were obtained
in time course experiments using BHK-21, Vero, and C33 cells
(data not shown).
IE gene expression is necessary for JNK activation. The
absence of JNK activity at early times p.i. argued against the
possibility that virions binding to cell surface receptors was
initiating a receptor-mediated signal cascade. In order to fully
negate the possibility of a delayed cell surface signal mediating
the induction of JNK, we performed kinase assays using virus
that had been neutralized with antibodies specific for different
viral envelope glycoproteins. Antibodies which bind to glyco-
proteins B, D, and H have been shown to neutralize virus by
blocking the virions’ ability to fuse with the cellular membrane
following initial attachment (23, 24, 66, 67). The glycoprotein
C monoclonal antibody, VII 13-7, does not prevent binding or
penetration, so that infection proceeds just as it would for virus
not incubated with neutralizing antibody (84).
The amount of each antibody (except that for gC) used to
neutralize virus reduced the titer by .2 logs as determined by
FIG. 4. Activation of JNK occurs with early kinetics. U2OS cells were mock
infected or infected with KOS (MOI 5 5) and harvested to produce cellular
lysates at the indicated times p.i. An equivalent number of cells was assayed in
each sample. (A) The top two panels show results from an experiment using 10
mg of GST-cJUN (aa 1 to 79) as the precipitating agent and substrate in kinase
reactions performed as described in Materials and Methods. The bottom two
panels are the results with 6 mg of GST-ATF2 (aa 1 to 254) as the precipitating
agent and substrate. (B) Cell-equivalent amounts of mock-infected and wild-type
KOS-infected U2OS cellular lysates prepared for JNK kinase assays and col-
lected at the indicated times p.i. were run on 10% polyacrylamide gels. Proteins
were transferred to a PVDF membrane and probed for activated p38 (p-p38) or
total p38 (p38). One-sixth the amount of protein was loaded onto gels to be used
for detecting total p38 as was loaded onto gels to be used for detecting activated
p38. (C) Samples of lysate were first precleared with normal rabbit serum and
protein A beads. ERK1 antibody was then added to precipitate the kinase.
Myelin basic protein (10 mg) was included in the kinase reaction as a substrate,
as described in Materials and Methods.
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plaque reduction assays. A roughly equivalent protein amount,
compared to monoclonal antibodies against gB, gD, and gH,
was used in experiments involving gC antibody. Additionally,
cells infected with virus which had been treated with the em-
pirically derived amounts of gB, gD, and gH neutralizing an-
tibody described above did not express viral proteins, while
cells infected with virus incubated with gC antibody expressed
representative viral proteins (immunoblot data not shown).
Virus treated with gB, gD, and gH neutralizing antibodies
prior to infection did not induce JNK activity in U2OS cells out
to 11 h p.i. (Fig. 5A). Nor did incubation of virus with gC
antibody prevent JNK induction. We conclude that virus bind-
ing to the surface of the cell is not sufficient for JNK activation,
nor is JNK activation seen in nonneutralized viral infections
due to a delayed signal cascade initiated at the cell surface.
Several virion proteins have additional functions upon en-
tering a newly infected cell. To determine if any of these
proteins were responsible for inducing JNK, we compared
mock-infected cell extracts to extracts from cells infected with
either wild-type virus or UV-irradiated virus over a time course
of infection. The inoculum of irradiated virus used in this
experiment had a titer that was reduced greater than 3 logs
relative to the control inoculum (data not shown). The exper-
iment presented in Fig. 5B shows that in U2OS cells, irradiated
virus, at best, minimally activated JNK. The magnitude of
activation was much less than that seen in infections with
unirradiated virus. Identical results were seen in repeat exper-
iments using Vero and C33 cells (data not shown). It is be-
lieved that UV-irradiated virus is impaired in its ability to
express detectable viral proteins upon infection due to thymine
dimers in the viral DNA impeding transcription of the genome
(38). We cannot, however, exclude the possibility that UV
irradiation may also cross-link some virion proteins and that
this action may be responsible for the inability of UV-irradi-
ated virus to induce high levels of JNK activity. To address this
concern, we used a temperature-sensitive viral mutant, tsB7. At
33°C, tsB7 grows normally, albeit more slowly than the parental
wild-type strain, HFEM. At 39.5°C, tsB7 virions can penetrate
cells, and the capsids move to the nuclear pores, but the viral
DNA is not released from the capsids into the nucleus (4). No
viral genes, therefore, are expressed at the restrictive temper-
ature (4, 51). tsB7 has been demonstrated to deliver functional
VP16 to the nucleus of infected cells at the restrictive temper-
ature (3a). The left panels of Fig. 4C show that at 33°C, mock-
infected cells do not activate JNK, but tsB7- and HFEM-in-
fected cells do with kinetics similar to that seen in KOS-
infected cells. The right-hand panels show that at 39.5°C, only
HFEM-infected cells significantly activate JNK. Activation ac-
tually occurs earlier at the higher temperature, for reasons we
do not understand at this time. tsB7-infected cells at 39.5°C
only induce a minimal level of JNK activity. From this result,
we conclude that de novo viral gene expression is necessary for
full JNK activation while virion proteins may activate JNK to
low levels.
A temporally regulated program of IE, early, and late viral
gene expression occurs following HSV infection (76). To de-
termine which virally encoded proteins were responsible for
activating JNK, we first compared the timing of JNK activation
with the expression and accumulation of representative pro-
teins of each of the viral kinetic classes of gene expression (Fig.
6A). By immunoblot analysis of the same extracts used in the
kinase assays, we could detect ICP4, an IE protein, within 1 h
p.i. and a rapid increase in expression peaking at 5 h p.i.
Expression of an early protein, ICP8, was first detected at 5 h
and increased out to 11 h. A late protein, glycoprotein C, was
not detected until 9 h p.i. Comparing the patterns of protein
expression (Fig. 6A) and JNK activation (Fig. 4A) revealed a
rise in kinase activity following a significant accumulation of
ICP4, but concurrently with the accumulation of ICP8 (Fig.
6A). This result could be interpreted in two ways. First, the
expression of an early protein(s) leads to activation of JNK.
Second, one or more IE proteins are responsible for JNK
activation, so that the results of IE protein activity, i.e., early
protein expression and JNK activation, occur simultaneously.
To distinguish between the two possibilities presented
above, we assayed JNK activity following infection by vi13, a
virus expressing an ICP4 with a 2-aa insertion at residue 338.
The insertion reduces the DNA binding affinity of ICP4 and
prevents early and late gene expression, while causing overex-
pression of IE proteins (82) (Fig. 6C). Infection of U2OS cells
with vi13 resulted in a twofold increase in JNK activity com-
pared to wild-type virus (Fig. 6B), indicating that expression of
early or late proteins was not necessary for JNK activation.
Based on this result and the fact that the timing of JNK acti-
vation was delayed relative to the binding and penetration of
the virus into the cell (Fig. 4A), the activation of JNK is likely
a result of the expression of one or more IE proteins. Addi-
tionally, if one or more IE proteins are responsible for activa-
tion, then the increased JNK activation observed in vi13-in-
fected cells could be explained by the overexpression of IE
proteins. Immunoblot analysis confirmed that vi13-infected
cells did not express representative early or late proteins, but
did overexpress IE proteins, e.g., ICP0 and ICP4 (Fig. 6C).
Activation of JNK enhances viral replication. Having docu-
mented activation of JNK following infection, we wished to
FIG. 5. Events prior to viral gene expression are not sufficient for JNK
activation. (A) U2OS cells were mock infected, infected with KOS (MOI 5 5),
or infected with KOS (MOI 5 5) previously incubated with an antibody specific
for viral gB (ss10), gC (VII 13-7), gD (III 174-1.2), or gH (52S). Cells were
harvested to produce cellular lysates at the indicated times p.i. Solid substrate
kinase assays were performed with GST-cJUN as described in Materials and
Methods. (B) U2OS cells were mock infected, infected with KOS (MOI 5 5), or
infected with KOS (MOI 5 5) that had been irradiated with UV light sufficiently
to reduce the effective titer by 3 logs. Cellular lysates were prepared at the
indicated times p.i., and in vitro solid substrate kinase assays were performed
with GST-cJUN as described in Materials and Methods. (C) U2OS cells prein-
cubated at 33 or 39.5°C were mock infected, infected with tsB7 (MOI 5 5 based
on titer at 33°C), or infected with HFEM, the strain from which tsB7 was derived.
Infections then proceeded at the indicated temperatures, and cellular lysates
were prepared at the indicated times p.i. In vitro solid substrate kinase assays
were performed with GST-cJUN as described in Materials and Methods.
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know if its activation was important for viral replication. To
address this question, we relied on the recently described in-
hibitor of JNK, JIP-1 (JNK-interacting protein-1). JIP-1 acts as
a cytoplasmic scaffolding protein that coordinates the trans-
duction of a signal through the SAPK pathway from the level
of MAPKKKs to JNK (93). JIP-1 binds exclusively to JNK and
not to other MAPKs, and it binds with a 100-fold greater
affinity to JNK than JNK binds to any of its substrates (17).
Overexpression of JIP-1 has been shown to effectively inhibit
JNK from translocating into the nucleus (independent of
JNK’s activation state) which prevents JNK-mediated gene
expression (93).
We created stable NIH 3T3 cell lines containing the
pcDNA3-JIP-1 expressing vector by G418 selection (see Ma-
terials and Methods). In the absence of an antibody to JIP-1 to
determine the expression level of JIP-1, we performed two
functional assays to prove that JIP-1 was acting to inhibit JNK.
First we performed GAL-cJUN-dependent CAT assays under
the premise that since JIP-1 inhibits JNK-mediated gene ex-
pression, GAL-cJUN-dependent CAT activity should be de-
creased in JIP-1-overexpressing cells compared to that in con-
trol cells. In one such cell line that stably contains the
pcDNA3-JIP-1 vector, G14.1, GAL-cJUN-dependent CAT ac-
tivity was decreased in both mock (basal) and infected (in-
duced) extracts compared to that in extracts from an empty
vector control cell line, G13.5 (Fig. 7A). To verify that JNK
was inhibited from translocating into the nucleus, we fraction-
ated mock- and virus-infected G13.5 and G14.1 cells and ran
extracts on gels to be used in immunoblotting for JNK. JNK
was primarily found in the cytoplasm of mock-infected (MC)
G13.5 and G14.1 cells, while very little JNK was detected in the
nucleus (MN). Upon infection, JNK was found in both the
cytoplasm (IC) and nucleus (IN) of G13.5 cells, but JNK was
still retained in the cytoplasm of G14.1 cells (Fig. 7B). Solid-
phase GST-cJUN-dependent kinase assays of extracts from
G13.5 and G14.1 cells indicated that JNK activation occurred
equally in both cell lines following infection (data not shown).
These results are consistent with the known properties of
FIG. 6. JNK activation is dependent upon viral IE gene expression. (A)
Cell-equivalent amounts of wild-type KOS-infected U2OS cellular lysates pre-
pared for JNK kinase assays were run on 12% polyacrylamide gels. Proteins were
transferred to a PVDF membrane and probed for viral proteins ICP4, ICP8, and
gC. (B) An in vitro solid substrate kinase assay was performed with GST-cJUN
as described in Materials and Methods with lysates prepared at the indicated
times p.i. from wild-type KOS- and vi13-infected cells (MOI 5 5). The kinase
data points were derived by scanning the autorads on an LKB laser densitometer.
(C) Immunoblot analysis of wild-type and vi13 ICPs was with the same antibodies
as in panel A, with the addition of ICP0.
FIG. 7. Preventing JNK from activating nuclear targets decreases the effi-
ciency of viral replication. (A) Two stably transfected NIH 3T3 cell lines, G13.5
(control cell line) and G14.1 (JIP-1 overexpressing cell line), were isolated as
described in Materials and Methods and compared for their ability to support
GAL-cJUN-dependent CAT activity. Cells were transfected with Lipofectamine
reagent with 2.5 mg of 53GAL-CAT and 500 ng of GAL-cJUN and then infected
with KOS (MOI 5 5) 24 h later. Eighteen hours p.i., the cells were harvested, and
CAT assays were performed as described in Materials and Methods. (B) G13.5
and G14.1 cells were mock infected or infected with KOS (MOI 5 5) for 8 h.
Cells were harvested, and fractionated extracts were prepared. Equal amounts of
protein from each fraction were run on 12% polyacrylamide gels. Proteins were
transferred to a PVDF membrane and probed for JNK. MC, mock-infected
cytoplasm; MN, mock-infected nucleus; IC, KOS-infected cytoplasm; IN, KOS-
infected nucleus. (C) The two cell lines were infected with HSV at an MOI of 5.
Cells and medium were harvested at the times indicated and frozen and thawed
four times. Titers of aliquots were determined on Vero cell monolayers.
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JIP-1. They also confirm that G14.1 cells are expressing JIP-1
so that JNK is unable to translocate into the nucleus and
activate its targets following infection. Single-step growth
curves for G13.5 and G14.1 cell lines demonstrated that inhib-
iting the ability of JNK to activate its targets decreased viral
yield by approximately 70% (Fig. 7C).
DISCUSSION
HSV induces cJUN and ATF2 trans-activation. Utilizing a
GAL-CAT reporter system, we have shown that the TADs of
cJUN and ATF2 were substantially activated following infec-
tion by HSV. This experimental approach eliminated any dif-
ferences in DNA binding that the transcription factors might
exhibit and allowed us to indirectly assess the activity of up-
stream kinases. cJUN and ATF2 TADs are activated by
SAPKs—cJUN by JNK and ATF2 by a p38 family member
(strongly) and by JNK (weakly) (33, 55, 73, 86). Although
ELK1 transcriptional activity can be induced by JNK or p38 as
well as ERK (7, 9, 28, 29, 32, 94, 96–98), it is clear that JNK is
not activating ELK1 under our experimental conditions. HSV
may be activating pathways that specifically target certain JNK
and p38 isoforms which in turn activate specific TADs. Three
JNK genes have been identified, giving rise to at least 10
alternatively spliced mRNAs, and different JNK isoforms have
different specificities and affinities for their respective sub-
strates (34). Additionally, there are at least four different p38
isoforms which are differentially activated by stress stimuli (13,
21, 73, 88). The activities of all other cellular transcription
factors we assayed decreased or were, at best, unchanged. The
decrease in GAL-RELA-dependent CAT activity following in-
fection agrees with a previous report that showed that NF-kB,
while translocated to the nucleus following infection, did not
demonstrate an increased ability to induce trans-activation
(68). At this time, we do not know if HSV is specifically inhib-
iting the activity of these factors or if the decreases are an
indirect effect of infection.
HSV infection has been shown to result in increased AP-1
activity (42). We used a CAT reporter containing two consen-
sus AP-1 binding sites in the promoter region to confirm this
finding (Fig. 1B). AP-1 can be composed of several different
JUN and FOS family members that all bind to consensus AP-1
sites, called TREs (3, 46). Since cFOS is not activated follow-
ing infection, but cJUN and ATF2 are, it is likely that increased
TRE-mediated trans-activation is a result of activated cJUN in
homodimers or in heterodimers with existing cFOS. Also of
note, the study by Tognon et al. (85) demonstrated downregu-
lation of cFOS expression by ICP4 which would result in de-
creased JUN-cFOS activity in favor of JUN-JUN and JUN-
ATF2 activity. Additionally, cJUN is capable of forming
heterodimers with ATF2 (3, 46). This heterodimer binds to
sites called CREs that differ from TREs by the addition of 1 bp
in the intervening sequence between the dyad repeats (3, 46).
We observed a cell-type-specific increase in CRE-dependent
CAT activity after HSV infection (Fig. 1B).
Activation of both cJUN and ATF2 could synergistically
activate to very high levels the expression of genes that contain
CREs in their promoters, such as the c-jun gene itself. It has
been shown that c-jun transcripts are induced following infec-
tion consistent with cJUN-ATF2 activation (42, 47). In the
study of Jang et al. (42) it was not possible to determine what
kind of probe was used to study AP-1 activation, but since most
of the assays used sequences derived from the c-jun promoter
which contains CREs, we conclude that their gel shifts reflect
increased CRE binding following infection. This interpreta-
tion, however, is in conflict with a recent report which demon-
strated that TRE-binding proteins but not CRE-binding pro-
teins accumulated (100). The latter study also showed that
while TRE-binding complexes increased, the relative propor-
tion of those complexes that contain cJUN decreased. These
results are not in contradiction to our results, since they as-
sayed DNA-binding activity of these transcription factors,
while we assayed their trans-activation property. AP-1 is a
complex transcription factor—it can be composed of several
different proteins that can bind to TREs and can differ in their
ability to activate transcription (46). Additionally, phosphory-
lation at specific sites on these proteins can enhance trans-
activation without changing DNA-binding or dimerization
properties (46). An important consideration in this regard is
that changes in DNA-binding activity do not mirror the regu-
lation of transcriptional activity (46). In order to measure the
ability of AP-1 (and its constituents) to activate transcription,
the trans-activation ability of those complexes must be mea-
sured with an appropriate reporter construct (46). Therefore,
even though the population of cJUN-containing AP-1 com-
plexes may be decreasing, the remaining cJUN is being acti-
vated by JNK. Likewise, even though CRE-binding proteins do
not increase after infection of BHK cells (100), the activity of
these proteins can be induced (Fig. 1B). Additionally, we can-
not rule out the possibility that other JUN family members,
such as JunB and JunD, which can bind to or be phosphory-
lated by JNK, respectively (45), are phosphorylated or mediate
the phosphorylation of dimerization partners after infection
and may be the true relevant targets in the infected cell.
RAS is a G-protein shown to be a key mediator of signaling
in many pathways (6, 87). There are pathways, however, that
do not involve RAS, and some downstream pathways are reg-
ulated by RAS only under certain conditions (5, 6, 61, 62, 87).
cJUN-dependent transcription can be weakly upregulated ei-
ther directly by activated RAS or indirectly by derepression of
pathways normally downregulated by active RAS, as seen in
Fig. 2B for the mock-infected extracts. The inability of either
dominant-negative RAS or constitutively active CDC25 to af-
fect the level of GAL-cJUN- or GAL-ATF2-dependent CAT
activity in HSV-infected cells suggests that HSV is capable of
stimulating cJUN and ATF2 TADs by a RAS-independent
mechanism(s). Bypassing any requirement for the upregulation
of RAS is in line with a study which showed that activated RAS
actually antagonized efficient viral replication. Infection of
RAS-transformed cells yielded less virus than nontransformed
cells of the same cell type (26).
HSV activation of JNK is dependent on IE gene expression.
To test the activities of different MAPKs, we performed im-
mune complex kinase assays to detect ERK activity and solid-
phase kinase assays to detect JNK activity. For the latter, we
have used a GST-cJUN (1 to 79 aa) construct to bind endog-
enous JNK and act as its substrate. Results from these exper-
iments indicated a 6- to 20-fold elevation, depending on the
cell type, in JNK kinase activity compared to that of mock
samples (Fig. 3A). We found no evidence for induction of JNK
at any time within the first hour of infection, corresponding to
when virus is binding to cell surface receptors. Activation typ-
ically began 3 to 4 h p.i., increased out to 8 h p.i., and remained
elevated out to at least 14 h p.i. (Fig. 4A, 5, and 6B). Since we
obtained identical results if we specifically immunoprecipitated
for JNK, in addition to the fact that the responsible kinase
must be able to bind to the N terminus of cJUN and only
phosphorylate Ser63 and Ser73, we conclude that we were
detecting bona fide JNK activity and not another cellular ki-
nase or a viral kinase with JNK-like properties.
Using a GST-ATF2 construct in solid-phase kinase assays,
we detected kinase activity that occurred with identical kinetics
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but a lower magnitude of activity than that detected with GST-
cJUN as a substrate (Fig. 4A). Since the ATF2 TAD can be
phosphorylated by both JNK and p38, we attempted to deter-
mine if p38 was activated by HSV. We took advantage of an
antibody that recognizes a phosphorylated form of p38 that
correlates with its being in an active state. We observed that
p38 is activated with identical kinetics to that seen for the
activation of JNK (compare Fig. 4B to 4A). MKK4 is activated
by HSV infection (100). Since MKK4 is a MAPKK that can
activate both JNK and p38, it is possible that HSV is activating
MKK4 to coordinate the activation of both SAPKs.
In contrast, over an 11-h-time-course experiment, we did not
detect any change in ERK activity (Fig. 4B). The binding of
growth factors to their cognate receptors and other growth-
promoting signals typically leads to ERK activation, which is
critical for inducing the expression of certain G1 and G1/S
phase-promoting proteins such as cyclin D (1a, 56, 67, 69, 75).
There are many examples drawn from studies of DNA viruses,
some of which are known to cause cell cycle progression, where
viral proteins cause activation of the ERK pathway. The E5
protein of bovine papillomavirus inhibits epidermal growth
factor (EGF) receptor (EGFR) and colony-stimulating factor
receptor down-regulation, leading to a persistence of activated
receptors at the cell surface (60). Vaccinia virus encodes a
virus growth factor that mimics EGF’s ability to stimulate
EGFR (50). ERK molecules are actually incorporated into the
human immunodeficiency virus type 1 virion, and ERK activity
is necessary for the disengagement of the reverse transcription
complex from the cell membrane and its translocation into the
nucleus (41). The herpesvirus saimiri protein STP-C488 asso-
ciates with RAS (43) and increases its GTP/GDP ratio, leading
to constitutive activation of ERK (44). Small T antigen of
simian virus 40 binds to and prevents protein phosphatase 2A
from dephosphorylating ERK2 and MEK, which prolongs
their activities (83). The inability to detect ERK activation
following HSV infection correlates with other evidence that
HSV infection fails to promote cell cycle progression (14, 19).
Whether the failure to promote progression is related to the
ability of HSV to encode most of its DNA replication machin-
ery, thus precluding the necessity to establish a true S phase,
remains to be determined.
Signals that lead to MAPK activation are often generated at
the cell surface when receptors bind to their appropriate li-
gand. Some studies have shown that when virus binds to a cell,
it may do so by binding to a cell surface receptor, and that
interaction may mimic normal ligand-receptor events to acti-
vate downstream pathways. Binding of simian immunodefi-
ciency virus (SIV) to cells activates ERK, JNK, and/or p38
depending upon the cell type, and hence, the receptor to which
SIV binds (71). Cytomegalovirus has been shown to generate
intracellular signals upon binding to the surface of permissive
cells that induce the translocation and activation of NF-kB (79,
99). One reported cell surface receptor for HSV, HVEM or
HveA, is a member of the tumor necrosis factor receptor
(TNFR) family (63, 91). Activation of this receptor in overex-
pression studies leads to the generation of a signal which up-
regulates AP-1 activities (59). This upregulation, though not
directly shown, is presumably due to induction of JNK, as many
TNFR family members have been shown to induce JNK lead-
ing to upregulated AP-1 activity (65, 74, 78). Even though the
cells we used do not express HVEM, HSV does bind to other
cellular receptors (27), and we predicted that binding to one or
more of these receptors may lead to MAPK activation. How-
ever, both the timing of JNK activation and the absence of
induction following infection by antibody-neutralized HSV,
which can bind but not enter cells, argue against this mecha-
nism.
Infection with UV-irradiated virus failed to induce JNK to
high levels. We believe the inability to activate JNK was due to
the inability of irradiated virus to express viral genes; however,
we could not discount potential cross-linking of virion proteins
as being responsible for the lack of JNK activity. We therefore
turned to a temperature-sensitive mutant which infects cells at
the restrictive temperature, delivers functional VP16 to the
nucleus (3a), but does not release viral DNA from capsids into
the nucleus (4). Viral genes, therefore, are not expressed in a
tsB7 infection at the restrictive temperature (4, 51), but tegu-
ment proteins are free to function normally. We failed to
detect high levels of JNK activity after infection by tsB7 at the
restrictive temperature. We did note that in UV-irradiated
virus extracts and tsB7 samples from 39.5°C, there was a slight
elevation in JNK activity over mock samples (approximately
twofold). It is possible that this slight activation was due to the
function of a tegument protein, such as VP16 (100). Alterna-
tively, it could reflect a low level of activation in the small
population of cells infected by less-damaged virus in UV-irra-
diated stocks or leaky tsB7 virus at the restrictive temperature,
mimicking an infection at a low MOI. We have noted that
activation is MOI sensitive, so that at an MOI of 0.5, the level
of JNK activation is very low (unpublished observation). These
results suggest that in order for HSV to significantly induce
JNK activity, the virus must enter the cell and express viral
genes.
Recently, JNK and p38 were reported to be activated after
HSV infection by a VP16-dependent mechanism (100). Com-
parisons of mock- and VP16 mutant in1814-infected cells in
that report were made difficult because of the very high back-
ground (mock-infected) levels of JNK activity. While we inter-
pret these results as at best arguing for a role for VP16 in JNK
activation, it is also possible that the defects in IE gene expres-
sion in in1814-infected cells may contribute to the failure to
detect JNK activation (1). Although the experiments with
in1814 were performed at a high MOI, it has not been directly
demonstrated that this condition of infection restores IE gene
expression to normal levels. The delayed activation kinetics of
JNK (3 to 4 h p.i.) observed by us and Zachos et al. (100) also
argue for at best an indirect role for VP16 and more directly a
role for one or more IE proteins in the mechanism of activa-
tion. An additional experimental approach by these authors, in
which transfection of wild-type VP16 and TAD-deleted VP16
expression vectors resulted in elevated JNK activity, did not
take into account the possibility that overexpressed protein
may in and of itself have resulted in a cellular stress response.
We were able to determine that expression of one or more
IE proteins was necessary for JNK activation. Infection with
vi13, an ICP4 mutant virus that only expresses IE proteins
(reference 82 and this report), led to activation of JNK with
identical kinetics to but greater magnitude than that of wild-
type virus, indicating that neither expression of early and late
genes nor viral DNA replication is necessary for activating
JNK. Supporting this conclusion was the observation that vi13-
infected cells overexpress IE proteins, which likely explains the
increased level of JNK activity compared to that of wild-type-
infected cells. Some of our current studies are attempting to
determine the level of JNK activity following infection with
viruses that are deleted for each viral IE gene. Due to func-
tional and physical interactions among different IE proteins,
we may also resort to using viruses that have multiple deletions
of IE genes in order to determine all of the relevant viral
proteins.
The above result is somewhat at odds with a similar exper-
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iment reported by Zachos et al. (100) in which infection with
the ICP4 mutant tsK at the restrictive temperature did not
induce increased JNK activation over wild-type virus. The in-
ability to detect a difference by using tsK may relate to the
small fold induction in JNK activity that these authors were
able to detect with wild-type virus. While they noted a maxi-
mum 4-fold increase in JNK activity over mock, we were able
to detect a 20-fold induction. We have been careful to modify
our infection and harvest protocols to minimize transient ac-
tivation of JNK which could have the effect of increasing back-
ground levels. Regardless, small differences in the level of JNK
activation, such as the 2-fold increase by vi13 over KOS would
be much easier to detect when KOS is activating JNK 20-fold.
Activation of JNK provides a beneficial activity for viral
replication. HSV infection causes many changes to the in-
fected cell, such as halting cellular macromolecular synthesis,
reorganizing the nucleus, and causing cells to round up before
they are ultimately lysed as a result of the release of viral
progeny (76). In this report, we describe an additional event,
the activation of SAPKs. Neither the mechanism for activation
nor its role in the infectious process of HSV is currently known.
The effect of JNK activation after infection could be complex
and cell-type specific, since activation of JNK under different
conditions in different cell types correlates with proliferation,
oncogenic transformation, or apoptosis (40, 92). Previously,
only four reports have described induction of JNK activity
following virus infection, and the significance of these induc-
tions is also unknown (20, 71, 81, 100).
JNK activation could represent a nonspecific or even an
antiviral response by the cell, but several factors argue against
this interpretation. First, our control experiments using mock-
infected cells or cells infected with neutralized, UV-irradiated
virus or tsB7 at the restrictive temperature demonstrate that
JNK activation is not a nonspecific response to the mechanics
of our infection procedure, due to growth factors or cytokines
in the inoculum, or related to early events occurring in lytic
infection. Additionally, the onset of JNK activation occurs 3 to
4 h p.i. By this time, virion components, such as VP16, have
had ample time to perform their ascribed functions, and IE
proteins have already reached high levels of accumulation. If
the cells were responding to the presence, accumulation, or
function of one or more of these proteins, a response would
likely have occurred sooner. The failure of UV-irradiated virus
or tsB7 at the restrictive temperature to induce JNK activity to
high levels demonstrated that virion components are incapable
of, or at least not sufficient for, activating JNK (Fig. 5). It is
possible though that VP16, for example, could minimally in-
duce JNK, as seen in UV-irradiated samples and tsB7 samples
at 39.5°C. Additionally, no early or late gene expression nor
any activity involved in viral DNA replication is necessary for
the activation of JNK in HSV-infected cells, as judged by the
results with the ICP4 mutant, vi13 (Fig. 6B).
In principle, virally encoded proteins could directly target
and thus alter the activity of cellular transcription factors (e.g.,
cJUN and ATF2). However, it appears that HSV is targeting
the upstream regulators of these factors, since increases in
their trans-activation function are accompanied by increased
JNK and p38 activity. We propose that expression of one or
more IE proteins leads to the activation of the JNK pathway.
Once activated, JNK would phosphorylate cellular transcrip-
tion factors that could enhance the expression of IE and pos-
sibly early viral genes. Promoters of IE, early, and late genes
contain cognate binding sites for a variety of cellular transcrip-
tion factors, e.g., Oct-1, Sp1, AP-1, CAAT, and NF-kB. Mu-
tation of these sites affects the efficiency of promoter function,
although no cellular transcription factors per se have been
demonstrated to serve an essential role in viral gene expression
(76). We also cannot rule out the possibility that JNK could be
targeting viral trans-activators ICP0, -4, and -27 to regulate
their roles in the temporal regulation of viral gene expression.
Alternatively, activation of SAPKs could be targeting cellular
activities and upregulating cellular genes that would lead to a
more conducive intracellular environment for viral replication.
By blocking the ability of JNK to act on its nuclear sub-
strates, we showed that virus yield is decreased by 70% (Fig.
7C), suggesting that HSV requires the action of this cellular
activity for efficient replication. While the decrease in viral
yield in JIP-1 expressing G14.1 cells is modest, several points
should be noted. First, JIP-1 overexpression did not completely
abrogate the ability of JNK to activate cJUN-dependent trans-
activation (Fig. 7A). Additionally, the activation of JNK in
NIH 3T3 cells following infection was weaker than in other cell
types, so viral replication may not be as dependent upon JNK
activity in NIH 3T3 cells as in other cell types, where JNK is
activated to higher levels. Finally much of the viral genome is
devoted to increasing the efficiency of replication in different
cell types (76, 89), and we would not expect that inhibiting one
cellular activity would completely block viral replication. A key
finding reported here, however, is that blocking a specific cel-
lular activity (the ability of JNK to activate its substrates) has
had a detrimental effect on replication. Patel et al. (68) re-
ported that blocking the infection-mediated translocation into
the nucleus of another cellular transcription factor, NF-kB,
reduced viral yield by 90%. The activity of E2F transcription
factors is reduced following infection by HSV as a result of an
increase in the association of these factors with regulatory
pocket proteins, such as pRB and p107 (39). Our findings in
conjunction with these reports suggest that a number of dif-
ferent cellular activities which target transcription factors are
being differentially manipulated in the infected cell and that
these activities, in total, are significant for the overall efficiency
of virus replication.
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1996. MKK3- and MKK6-regulated gene expression is mediated by the p38
mitogen-activated protein kinase signal transduction pathway. Mol. Cell.
Biol. 16:1247–1255.
74. Reinhard, C., B. Shamoon, V. Shyamala, and L. T. Williams. 1997. Tumor
necrosis factor-a-induced activation of c-jun N-terminal kinase is mediated
by TRAF2. EMBO J. 16:1080–1092.
75. Robinson, M. J., and M. H. Cobb. 1997. Mitogen-activated protein kinase
pathways. Curr. Opin. Cell Biol. 9:180–186.
76. Roizman, B., and A. E. Sears. 1996. Herpes simplex viruses and their
replication, p. 2231–2295. In B. N. Fields, D. M. Knipe, and P. M. Howley
(ed.), Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
77. Rong, B. L., T. A. Libermann, K. Kogawa, S. Ghosh, L.-X. Cao, D. Pavan-
Langston, and E. C. Dunkel. 1992. HSV-1 inducible proteins bind to NFkB-
like sites in the HSV-1 genome. Virology 189:750–756.
78. Sakata, N., H. R. Patel, N. Terada, A. Aruffo, G. L. Johnson, and E. W.
Gelfand. 1995. Selective activation of c-Jun kinase-activated protein kinase
by CD40 on human B cells. J. Biol. Chem. 270:30823–30828.
79. Sambucetti, L. C., J. M. Cherrington, G. W. Wilkinson, and E. S. Mocarski.
1989. NFkB activation of the cytomegalovirus enhancer is mediated by a
viral transactivator and by T cell stimulation. EMBO J. 8:4251–4258.
80. Schmitz, M. L., M. A. dos Santos Silva, and P. A. Baererle. 1995. Trans-
activation domain 2 (TA2) of p65 NF-kB. J. Biol. Chem. 270:15576–15584.
81. See, R. H., and Y. Shi. 1998. Adenovirus E1B 19,000-molecular-weight
protein activates c-Jun N-terminal kinase and c-Jun-mediated transcription.
Mol. Cell. Biol. 18:4012–4022.
82. Shephard, A. A., and N. A. DeLuca. 1991. Activities of heterodimers com-
posed of DNA-binding- and transactivation-deficient subunits of the herpes
simplex virus regulatory protein ICP4. J. Virol. 65:299–307.
83. Sontag, E., S. Fedorov, C. Kamibayashi, D. Robbins, M. Cobb, and M.
Mumby. 1993. The interaction of SV40 small tumor antigen with protein
phosphatase 2A stimulates the MAP kinase pathway and induces cell pro-
liferation. Cell 75:887–897.
84. Spear, P. Personal communication.
85. Tognon, M., M. G. Romanelli, E. M. Cattozzo, C. Bovolenta, and E. Liboi.
1993. C-fos proto-oncogene transient transcription is negatively affected in
the ELa4-2 transformed cell line. Pathobiology 61:288–292.
86. van Dam, H., D. Wilhelm, I. Herr, A. Steffen, P. Herrlich, and P. Angel.
1995. ATF-2 is preferentially activated by stress-activated protein kinases to
mediate c-jun induction in response to genotoxic agents. EMBO J. 14:1798–
1811.
87. Vojtek, A. B., and C. J. Der. 1998. Increasing complexity of the RAS
signaling pathway. J. Biol. Chem. 273:19925–19928.
88. Wang, X. S., K. Deiner, C. L. Manthey, S.-W. Wang, B. Rosenzweig, J. Bray,
J. Delaney, C. N. Cole, P.-Y. Chan-Hui, N. Mantlo, H. S. Lichenstein, M.
Zukowski, and Z. Yao. 1997. Molecular cloning and characterization of a
novel p38 mitogen-activated protein kinase. J. Biol. Chem. 272:23668–
23674.
89. Ward, P. L., and B. Roizman. 1994. Herpes simplex genes: the blueprint of
a successful human pathogen. Trends Genet. 10:267–274.
90. Westwick, J. K., A. D. Cox, C. J. Der, M. H. Cobb, M. Hibi, M. Karin, and
D. A. Brenner. 1994. Oncogenic RAS activates c-JUN via a separate path-
way from the activation of extracellular signal-regulated kinases. Proc. Natl.
Acad. Sci. USA 91:6030–6034.
91. Whitbeck, J. C., C. Peng, H. Lou, R. Xu, S. H. Willis, M. Ponce De Leon, T.
Peng, A. V. Nicola, R. I. Montgomery, M. S. Warner, A. M. Soulika, L. A.
Spruce, W. T. Moore, J. D. Lambris, P. G. Spear, G. H. Cohen, and R. J.
Eisenberg. 1997. Glycoprotein D of herpes simplex virus (HSV) binds
directly to HVEM, a member of the tumor necrosis factor receptor super-
family and a mediator of HSV entry. J. Virol. 71:6083–6093.
92. Whitmarsh, A. J., and R. J. Davis. 1996. Transcription factor AP-1 regu-
lation by mitogen-activated protein kinase signal transduction pathways. J.
Mol. Med. 74:589–607.
93. Whitmarsh, A. J., J. Cavanagh, C. Tournier, J. Yasuda, and R. J. Davis.
1998. A mammalian scaffold complex that selectively mediates MAP kinase
activation. Science 281:1671–1674.
94. Whitmarsh, A. J., S.-H. Yang, M. S.-S. Su, A. D. Sharrocks, and R. J. Davis.
1997. Role of p38 and JNK mitogen-activated protein kinases in the acti-
vation of ternary complex factors. Mol. Cell. Biol. 17:2360–2371.
95. Woodgett, J. R., J. M. Kyriakis, J. Avruch, L. I. Zon, B. Zanke, and D. J.
Templeton. 1996. Reconstitution of novel signaling cascades responding to
cellular stresses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351:135–142.
96. Yang, D., C. Tournier, M. Wysk, H. T. Lu, J. Xu, R. J. Davis, and R. A.
Flavell. 1997. Targeted disruption of the MKK4 gene causes embryonic
death, inhibition of c-Jun NH2-terminal kinase activation, and defects in
AP-1 transcriptional activity. Proc. Natl. Acad. Sci. USA 94:3004–3009.
97. Yang, S. H., A. J. Whitmarsh, R. J. Davis, and A. D. Sharrocks. 1998.
Differential targeting of MAP kinases to the ETS-domain of transcription
factor Elk-1. EMBO J. 17:1740–1749.
98. Yang, S.-H., P. R. Yates, A. J. Whitmarsh, R. J. Davis, and A. D. Sharrocks.
1998. The Elk-1 ETS-domain transcription factor contains a mitogen-acti-
vated protein kinase targeting motif. Mol. Cell. Biol. 18:710–720.
99. Yurochko, A. D., E.-S. Hwang, L. Rasmussen, S. Keay, L. Pereira, and E.-S.
Huang. 1997. The human cytomegalovirus UL55 (gB) and UL75 (gH)
glycoprotein ligands initiate the rapid activation of Sp1 and NF-kB during
infection. J. Virol. 71:5051–5059.
100. Zachos, G., B. Clements, and J. Conner. 1999. Herpes simplex virus type 1
infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase
pathways and activates transcription factor AP-1. J. Biol. Chem. 274:5097–
5103.
8426 MCLEAN AND BACHENHEIMER J. VIROL.
